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Abstract
Background: Diarrhea and mortality resulting from infections with enteropathogenic Escherichia
coli (EPEC) are of major economic importance in the rabbit meat industry. There is a growing need
for an effective vaccine to cope with these problems and to reduce the use of antibiotics. EPEC are
characterized by an attaching and effacing virulence mechanism. This is partly mediated by the
intimate binding between an adhesin, called intimin, and a translocated receptor (Tir) of prokaryote
origin. We constructed an intimin deletion mutant of the rabbit EPEC (REPEC) wild-type strain 97/
241.6 (bio-/serogroup 3-/O15) and examined its protective capacity.
Results: After verifying its complete loss of virulence, we used the attenuated strain in vaccination-
challenge experiments in which complete protection against a homologous, but virulent, strain was
observed. The attenuated strain was able to persist in the intestinal lumen, where it elicited an
immune response against EPEC-related virulence proteins, as was shown using an EspB-specific
ELISA. Despite the priming of an immune response and the generation of specific antibodies, the
intimin mutant was not able to fully protect rabbits against challenges with REPEC strains of other
bio-/serogroups.
Conclusion: These data indicate that protection against REPEC infections is at least partly bio-/
serogroup dependent and a multivalent vaccine may be needed for protection against the full range
of REPEC types. Such a combination vaccine may be developed using intimin null mutants, as the
latter were clearly shown to be safe and effective against homologous infections.
Background
Enteropathogenic Escherichia coli (EPEC) strains are an
important cause of human and animal diarrhea. In
humans, EPEC are a substantial cause of infant mortality
in developing countries. In rabbit production, especially
newly weaned animals are highly vulnerable to EPEC. The
attaching and effacing virulence mechanism of EPEC is
encoded by the chromosomal locus of enterocyte efface-
ment (LEE) [1,2]. After initial adherence, EPEC translo-
cate their intimin receptor (Tir) and other proteins to the
eukaryotic host cell by means of an LEE encoded type III
secretion apparatus. Positioning of Tir in the host cell
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membrane makes the interaction possible with intimin,
the outer membrane adhesin encoded by eae [3,4]. This
adhesin-receptor binding leads to an intimate contact
between the bacterium and the host cell, resulting in the
effacement of the microvilli and the formation of actin-
rich pedestals beneath the adherent EPEC [5,6].
Compared to EPEC in humans [7], only a limited number
of bio-/serogroups have been described for rabbit EPEC
(REPEC). While one bio-/serogroup (1+/O109) is mainly
pathogenic to suckling rabbits, other REPEC are more (3-
/O15, 4+/O26, 8+O103) or less (2+/O128, 2+/O132)
pathogenic to weaned rabbits [8]. The economic losses in
rabbit production are hard to control because many anti-
microbial agents cannot be used in rabbits, while at the
same time many EPEC strains are resistant to the drugs
commonly used [7,9].
Although much work has been done on unraveling the
molecular pathogenesis of EPEC, it is still not clear which
antigens induce protection against an infection. Experi-
mental treatment using formalin-killed REPEC as a vac-
cine against challenges with E. coli 8+/O103 proved to be
impractical due to the high vaccination dose and the
repeated administrations that were needed. Apathogenic
E. coli isolates that carried only the colonizing factor of the
E. coli 8+/O103 bio-/serogroup also turned out to be
impractical for use as a REPEC vaccine [10,11]. Recently,
an 8+/O103 REPECΔ(tir/espB)mutant was shown to pro-
tect rabbits against this highly virulent bio-/serogroup
[12]. EPEC mutants defective in the intimin encoding eae
gene do not induce reorganization of the cytoskeletal
structure underneath the site of attachment, and therefore
do not form pedestals [13,14]. Based on this knowledge,
we constructed a REPEC mutant incapable of reversion to
the wild-type due to a disruption of the eae gene. The
safety and protective capacity of this mutant for weaned
rabbits was examined in detail.
Results
Construction of mutant 97/241.6Δeae (3-/O15)
Only one out of 294 colonies tested had lost the 248 bp
region and generated a PCR band of the expected 102 bp,
compared to 350 bp for the wild-type strain (Figure 1).
The deficiency in expression of intimin (~97 kDa) was
verified by Western blotting using sera derived from a
REPEC infected rabbit (Figure 2).
In vitro brush border adhesion assay
The observations with the fluorescence microscope clearly
demonstrated that low numbers of 97/241.6Δeae bacteria
were able to adhere to the brush borders of the isolated
rabbit intestinal villi. Similarly low numbers of adhering
bacteria were observed in the case of the wild-type 97/
241.6 and 97/223.10 strains (data not shown). The DH5α
strain did not adhere to the isolated villi, whereas the B10
strain adhered abundantly, as shown in Figure 3.
Animal experiments
In vivo virulence of mutant 97/241.6Δeae
To verify the safety of the mutant strain, one control and
three groups of rabbits, which were administered different
concentrations of the 97/241.6Δeae strain, were examined
closely over a period of four weeks.
On arrival, no rabbits were found positive for EPEC,
Clostridium spiroforme or rotavirus. Eimeria  spp. were
detected in only small numbers in two rabbits. During the
PCR amplification of part of the eae gene comprising the  deleted 248 bp fragment, using primers 248 FOR and 248  REV Figure 1
PCR amplification of part of the eae gene comprising the 
deleted 248 bp fragment, using primers 248 FOR and 248 
REV. The amplification product of the mutant strain 97/
241.6Δeae is shown in lane 2, and that of the wild-type 97/
241.6 strain in lane 3. A 100 bp GeneRuler (Fermentas) was 
used as a size-marker (lane 1).BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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period of the study, no adverse effects due to the Baycox
treatment were observed. At the end of the study, no
symptoms of coccidiosis were noted at necropsy.
During the entire experiment, none of the 97/241.6Δeae-
inoculated rabbits showed any sign of diarrhea. Moreover,
no significant differences were observed between the four
groups, including the non-infected controls, for any of the
parameters examined. Mutant strain 97/241.6Δeae  was
isolated from the first day and up to three weeks after
inoculation, albeit in low numbers.
Vaccination experiment with a homologous challenge after seven 
days
During an experiment lasting five weeks, the efficacy of
vaccination against a homologous challenge as early as 7
days post-vaccination was examined in vivo using three
groups of rabbits: a vaccinated-challenged group (group
In vitro attachment of fluorescent E. coli strains to isolated  intestinal villi Figure 3
In vitro attachment of fluorescent E. coli strains to isolated 
intestinal villi. The 97/241.6Δeae REPEC (A) do adhere, but 
only in small numbers. The insert shows three mutant bacte-
rial cells attached to the enterocytes. DH5α strains (B) do 
not adhere to the intestinal villi, while B10 strains (C) are 
strongly adherent. The insert shows multiple E. coli (intense 
green) attached to the brush border (faint green).
Immunoblot of the total protein fraction of strain 97/ 241.6Δeae (lane 2) and wild-type strain 97/241.6 (lane 3) Figure 2
Immunoblot of the total protein fraction of strain 97/
241.6Δeae (lane 2) and wild-type strain 97/241.6 (lane 3). A 
biotinylated broad-range standard (lane 1) was used as a 
marker (BioRad). The intimin band (~97 kDa), marked with 
an arrow, is clearly present in the wild-type strain, but absent 
in the deletion mutant.BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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1), an unvaccinated-challenged group (group 2), and a
control group (group 3).
No differences were observed between the groups before
challenge. After challenge, the group of non-vaccinated
but challenged animals (group 2) suffered heavily from
diarrhea, while no diarrhea was observed in rabbits
belonging to the vaccinated group (group 1) or to the neg-
ative control group (group 3). Even though the challenge
dose was low (5.4 × 104 CFU), one of the non-vaccinated
animals died from colibacillosis, as was demonstrated by
lesions observed at necropsy and isolation of the chal-
lenge strain from the cecal content. Non-vaccinated chal-
lenged animals systematically showed a lower weight gain
compared to vaccinated and negative control animals,
although the difference was not significant. The feed
intake of the non-vaccinated challenged animals was sig-
nificantly reduced one week after challenge compared to
the negative control (P = 0.023) and the vaccinated rab-
bits (P = 0.043). The rabbits recovered slowly in the fol-
lowing weeks and the differences in feed intake
disappeared. Between the vaccinated and the control
group, no significant differences in feed intake were
detected at any time during the experiment (Figure 4).
Vaccination experiment with a homologous challenge after four 
weeks
During an experiment that lasted eight weeks, the efficacy
of vaccination against a homologous challenge after four
weeks was examined in vivo using three groups of rabbits:
a vaccinated-challenged group (group 1), an unvacci-
nated-challenged group (group 2), and a control group
(group 3).
Before challenge, no apparent differences between the
groups were observed. Even after challenge with 106 CFU
of a virulent strain, no differences were observed between
the vaccinated group (group1) and the negative control
group (group 3). However, during the first two weeks after
challenge, the animals of the non-vaccinated group
(group2) showed clear signs of diarrhea and differed sig-
nificantly from the vaccinated and control groups for both
feed intake (P  < 0.001, shown in Figure 5) and body
weight (P < 0.001, results not shown).
Low numbers of the vaccine strain were shed for up to 3
weeks after vaccination with a peak at the end of the first
week. After challenge, only the wild-type strain was
detected, as was verified by PCR. Semi-quantitative analy-
sis of the shedding of E. coli showed a clear difference
between the vaccinated and the non-vaccinated groups
(Figure 6). The non-vaccinated animals shed the wild-type
Vaccination experiment followed by challenge with a homol- ogous strain after 28 days Figure 5
Vaccination experiment followed by challenge with a homol-
ogous strain after 28 days. Average feed intake of the differ-
ent groups of rabbits plotted against day after vaccination. 
Vaccination with strain 97/246.1Δeae was performed imme-
diately after weaning. Both the vaccinated and non-vaccinated 
groups were challenged at day 28 after vaccination (arrow) 
with strain 97/223.10. Significant differences between the 
non-vaccinated and the other groups are indicated with 
asterisks (***: P < 0.001; **:P < 0.01; *:P < 0.05).
Vaccination experiment followed by challenge with a homol- ogous strain after seven days Figure 4
Vaccination experiment followed by challenge with a homol-
ogous strain after seven days. Average feed intake of the dif-
ferent groups of rabbits plotted against number of days after 
challenge. One group was vaccinated with strain 97/
246.1Δeae seven days before challenge (day -7; i.e. immedi-
ately after weaning), while both the vaccinated and the non-
vaccinated group were challenged (day 0) with REPEC 97/
223.10 wild-type strain. Significant differences between the 
non-vaccinated and the other groups are indicated with an 
asterisk (*:P < 0.05).BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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strain in high numbers, whereas the vaccinated rabbits
shed the virulent strain in only limited numbers.
Vaccination experiment with heterologous challenge after four weeks
At the beginning of a third vaccination-challenge experi-
ment, three groups of weaned rabbits were vaccinated
with strain 97/241.6Δeae. Four weeks later, these and
three other groups of rabbits were challenged with heter-
ologous virulent strains and were examined for another
four weeks. A seventh group (group 1) was included as a
negative control. No significant differences were detected
between the groups for the observed parameters during
the first four weeks. After challenge (day 28), the feed
intake of the control group differed significantly from all
other groups (P < 0.001), with the exception of group 6
(vaccinated and infected with the 4+/O26 strain) (Figure
7). The latter group also differed significantly from group
7 (non-vaccinated and infected with the 4+/O26 strain) as
a function of time (P = 0.028). No significant differences
in feed intake were observed between vaccinated and non-
vaccinated groups challenged with other heterologous
strains (Figure 7). Similar results were observed for weight
gain (data not shown).
After challenge, diarrhea was observed in all groups except
for the control group. The diarrhea scores of the two
groups infected with a virulent 2+/O132 strain were alike.
In both groups, two rabbits showed severe signs of
diarrhea. The two groups infected with the 8+/O103 strain
had similar diarrhea scores as well, with three rabbits of
the non-vaccinated group (group 5) and four rabbits of
the vaccinated group (group 4) showing severe diarrhea.
Again, a difference was observed between the groups chal-
lenged with the 4+/O26 strain. In the non-vaccinated
group (group 7), five rabbits showed severe diarrhea for
more than one week. Three of these rabbits died before
the end of the experiment. In the vaccinated group (group
6), only two rabbits showed mild diarrhea for only three
days. In this group, none of the rabbits died.
EspB-specific ELISA
The concentration of the recombinant EspB solution was
estimated to be around 0.7 mg purified protein per ml
and was diluted to one μg per ml to coat the microtiter
plates. As shown in Figure 8, the titers of EspB-specific
antibodies are significantly higher from day 14 onward
for the vaccinated compared to the non-vaccinated groups
of the second challenge experiment (P = 0.01).
Discussion
Diarrhea caused by REPEC is a major problem for rabbit
production. In this study we constructed an intimin null
mutant and tested its protective potential in vaccination-
challenge experiments.
The safety of the live attenuated 97/241.6Δeae strain was
clearly demonstrated, both by the in vivo virulence test
and by the three challenge experiments. This is in accord-
ance with the loss of virulence for an intimin null mutant
of an attaching and effacing Citrobacter rodentium strain
[15], but in contrast to a human E2348/69Δeae strain that
Vaccination experiment followed by challenge with heterolo- gous strains after 28 days Figure 7
Vaccination experiment followed by challenge with heterolo-
gous strains after 28 days. Average feed intake of the differ-
ent groups of rabbits plotted against day after vaccination. 
Vaccination with strain 97/246.1Δeae (3-/O15) took place 
immediately after weaning. All groups, with the exception of 
the control group, were challenged at day 28 after vaccina-
tion (arrow) with a virulent strain of the bio-/serogroup indi-
cated in the legend.
A semi-quantitative assessment of the shedding of the vac- cine strain (before day 28) and wild-type strain (after day 28) Figure 6
A semi-quantitative assessment of the shedding of the vac-
cine strain (before day 28) and wild-type strain (after day 28). 
The day of infection is indicated by the arrow. Grey bars rep-
resent the shedding by the vaccinated animals, black bars the 
shedding by the non-vaccinated rabbits (0 = no shedding, 4 = 
confluent colonies on agar plate).BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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produced signs of diarrhea in 4 out of 11 infected volun-
teers [13]. The latter results might be explained by the
presence of additional virulence factors in human EPEC
strains, such as a cytolethal distending toxin that has been
described for the E2348/69 strain [16] and not for REPEC
so far.
Our vaccination-challenge experiments showed that the
97/241.6Δeae  strain offers complete clinical protection
against infection with a homologous 3-/O15 virulent
REPEC strain. This was observed whether the challenge
took place one or four weeks after vaccination. During
both in vivo experiments, the rabbits of the vaccinated
groups showed a significantly higher feed intake than
those of the non-vaccinated groups. The lack of a signifi-
cant difference between the weights of the animals during
the first challenge experiment was likely due to the lower
infection dose. The increase of the dose in the second
challenge experiment resulted in more severe clinical
signs and a significant difference in weight between the
vaccinated and the non-vaccinated group. Similarly, a 4+/
O26 C230Δeae mutant had no remaining virulence and
was also able to protect rabbits against a later infection
with a pathogenic C230 wild-type strain (see Additional
File 1). Moreover, a recent report showed similar results
for an 8+/O103 REPECΔ(tir/espB) mutant which also tar-
gets the intimin-Tir interaction [12]. These three inde-
pendent results substantiate that attenuated strains with a
deletion in the genes responsible for intimate binding are
avirulent and can be used to protect rabbits against infec-
tion with homologous REPEC for up to at least four weeks
after vaccination. Since meat rabbits are normally slaugh-
tered at 10 or 11 weeks of age, and since they are most sus-
ceptible to colibacillosis during the first two weeks after
weaning (at the age of five to six weeks), a single vaccina-
tion at weaning may suffice to protect the animals against
REPEC during their entire life span. However, further
studies are needed to confirm this hypothesis since a sim-
ilar vaccination experiment failed to fully protect individ-
uals against experimental infection with a virulent human
EPEC strain 70 days after vaccination [17]. Together with
the decline of the local immune response over time, the
high infection dose used during the latter study may have
contributed to the results observed.
In an earlier study it was shown that both intimin and a
REPEC adherence locus (ral) were required for the coloni-
zation of a 3-/O15 REPEC strain [18]. These results are in
agreement with our in vitro adhesion studies and shedding
data. Apparently, the mutant strain is able to adhere and
persist in the intestine for over three weeks, albeit in low
numbers. This persistence of the mutant strain was suffi-
cient to elicit a specific immune response, as was shown
by an EspB specific ELISA, and to protect the animals
against colonization by a homologous pathogenic strain.
Conversely, only partial protection – if any – was
observed when the rabbits were challenged with heterolo-
gous REPEC strains. The 3-/O15 mutant was largely pro-
tective against a challenge with a virulent 4+/O26 strain,
but failed to protect rabbits against the virulent 8+/O103
and 2+/O132 strains.
It is unlikely that the lack of cross-protection between
REPEC types is the result of different subtypes of LEE
encoded proteins. Different subtypes of LEE-related pro-
teins have been described for a number of hosts [19,20],
but whether this is also the case for rabbits and whether
these subtypes may influence protection is questionable.
Also whether or not the outer membrane lipopolysaccha-
rides elicit a protective immune response remains to be
elucidated. Many cross-reactions between polysaccharides
have been described [21], but to our knowledge, no data
are available about cross-reactivity between the sero-
groups studied [22]. Experiments in chickens with fim-
brial antigens and lipopolysaccharides as potential
vaccine candidates showed promising results [23]. How-
ever, a subsequent study by the same research unit [24]
also showed a lack of protection against a heterologous
challenge.
Colonization factors, possibly related to certain sero-
groups, may also explain our observed results. Several
fimbriae have already been determined to enhance path-
ogenicity [25-27], but the relation of colonization factors
to bio-/serogroup needs further study. So far, the expres-
sion of AF/R2 has only been described in 8+/O103 strains
[27], while a ral encoded adhesin has been described for a
3-/O15 strain [25].
A: Detection of the EspB-specific serum antibodies of non- vaccinated and vaccinated rabbits as a function of time Figure 8
A: Detection of the EspB-specific serum antibodies of non-
vaccinated and vaccinated rabbits as a function of time. 
Groups of 12 rabbits were used. The means were signifi-
cantly different (P = 0.01) from day 14 onward. B: SDS-PAGE 
followed by silver-staining of a molecular weight standard (1) 
and purified recombinant EspB (2). The EspB band of approx-
imately 40 kDa is clearly visible.BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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Conclusion
Our experiments indicate that an eae deletion mutant may
prove to be an effective, practical and safe vaccine candi-
date for protection against homologous challenges, but it
cannot completely protect against heterologous virulent
REPEC strains. Our study may also be helpful in the proc-
ess of understanding the pathogenesis of EPEC in
humans. The extensive genome and protein conservation
between rabbits and primates [28] and the fact that
REPEC pathogenesis shows more similarities with human
EPEC infections [29,30] than do the commonly used
C.rodentium infections in mice, make the rabbit an inter-
esting animal model. Further studies using deletion
mutants targeting other antigens may help to elucidate
which factors are protective. In the mean time, the use of
a combination vaccine consisting of the main REPEC bio-
/serogroups may prove an effective tool in the control of
colibacillosis in rabbits.
Methods
Bacterial strains, plasmids and media
The REPEC strains 97/241.6 (3-/O15), 97/223.10 (3-/
O15), 82/90 (2+/O132), 97/110.6 (8+/O103) and 00/
195.1 (4+/O26) were Belgian field isolates. REPEC B10
and RDEC-1 are described elsewhere [31]. The DH5α and
Top10F' cells used in this study are commercially availa-
ble (Invitrogen, UK). The 97/241.6Δeae strain constructed
in this study was selected for tetracycline sensitivity by the
method of Bochner et al. [32] and was deposited under
No. P-18935 on April 22, 1999 in the Belgian Coordi-
nated Collections of Microorganisms (LMG, Ghent, Bel-
gium).
The pRSET-B expression and pCR2.1-TOPO vectors were
used according to the manufacturer's instructions (Invit-
rogen). The pKO3 suicide plasmid is described in detail by
Link et al. [33].
E. coli were grown in Luria-Bertani Broth (LB) or on LB
agar (LA) and stored at -80°C in LB containing 50% glyc-
erol. Ampicillin (50 μg/ml) was added where appropriate.
SOC medium (Sigma, Mo., USA) was used to revitalize
cells after transformation. For inoculation purposes,
strains were grown in Penassay broth (Difco, Md., USA).
Construction of mutant 97/241.6Δeae (3-/O15)
The sequence of the eae gene of strain 97/241.6 was deter-
mined (Genbank accession no. AY255520). The gene was
amplified using 2 U of Expand™ polymerase (Roche Diag-
nostics, Switzerland) and 20 pmol of both EAE RDEC-1
FOR and REV primer (Table 1), and then ligated in a
pCR2.1-TOPO vector. Next, the insert was cut out using
BamHI and ligated in a BamHI restricted pKO3 vector,
resulting in pKO3::eae. After ligation, an internal 248 bp
region of eae was removed by PstI digestion and self-liga-
tion. Electroporation of the pKO3::Δeae vector obtained
in REPEC strain 97/241.6 was performed using 0.2 cm
cuvettes in a Gene Pulser apparatus (BioRad, Ca., USA) at
200Ω ; 2.3 kV; and 25 μF. The chromosomal gene replace-
ment was performed as described by Link et al. [33]. Can-
didate mutants were selected and tested by PCR using
primers flanking the deleted 248 bp (primers 248 FOR
and REV in Table 1). The loss of expression of intimin was
confirmed using SDS-PAGE followed by silver staining
and Western blotting by a method adapted for semi-dry
transfer [34]. An SDS-PAGE broad-range standard was
used as a marker (BioRad).
Expression and purification of recombinant EspB
A set of EspB primers (Table 1), which includes the hexa-
nucleotide recognition site of BamHI and HindIII, was
used to amplify the espB gene of REPEC strain 97/241.6.
The resulting PCR fragment was cloned in a pCR2.1-
TOPO vector and subsequently excised using HindIII and
BamHI for ligation in a double restricted pRSET-B-vector.
The resulting pRSET::espB vector was transformed in elec-
trocompetent Top10F' cells as described above.
To express the recombinant EspB, 50 ml of LB medium
containing ampicillin was inoculated with 1 ml overnight
culture of Top10F'/pRSET::espB cells, while 50 mmol of
IPTG and 5.1010PFU of bacteriophage M13 were added
after one and three hours of incubation at 37°C, respec-
tively. After four hours of incubation, the cells were har-
vested and the recombinant EspB protein, which contains
a His-tag, was purified by means of Ni2+-affinity chroma-
tography (Xpress purification kit, Invitrogen). The eluates
were checked for purity using silver staining and Western
blotting as described above. The concentration of the
recombinant EspB eluates was estimated using the micro
BCA protein assay (Pierce, Il., USA) (Figure 7).
EspB-specific ELISA
Affinity-purified recombinant EspB was coated onto 96-
well microtitre plates overnight at 4°C at a concentration
of 1 μg per ml coating buffer (15 mM Na2CO3, 35 mM
NaHCO3, 3 mM NaN3; pH 9.6). The next day, the plates
were washed three times with washing buffer (150 mM
NaCl, 10 mM Na3PO4, 0.05% (v/v) Tween-20; pH7.2).
After washing, the plates were blocked with coating buffer
containing 5% (w/v) bovine serum albumin for one hour
at room temperature. Subsequently, the plates were
washed as described above and rabbit serum was added at
a dilution of 1:100. The rabbit sera of the vaccinated and
non-vaccinated groups of the second challenge experi-
ment were used to monitor the EspB specific antibody
response. Following incubation at room temperature for
two hours, the plates were washed and incubated for one
hour with biotinylated donkey anti-rabbit immunoglobu-
lins diluted 1 to 3000 (Amersham, UK). After washing,BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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peroxidase streptavidin conjugate (Roche Diagnostics)
was added for one hour at room temperature at a dilution
of 1:3000. After washing the plates four times, the bound
antibodies were detected using the TMB microwell perox-
idase substrate (Kierkegaard & Perry Laboratories, Md.,
USA). After five minutes, 1 M H3PO4 was added to stop
the reaction and the optical density was measured at 450
nm.
In vitro brush border adhesion assay
Intestinal villi of a six-week-old New-Zealand rabbit
(Versele-Laga, Belgium) were harvested using a previously
described technique [35,36]. The E. coli strains were FITC-
labeled by incubating 108 microorganisms during 30 min-
utes with a 0.1 M Na2CO3 solution containing 0.5 mg
FITC (Sigma) per ml. After the bacteria were washed sev-
eral times with PBS containing 1% mannose, they were
incubated together with the villi for one hour at room
temperature. After incubation, the villi were washed five
times with PBS to eliminate non-adhering bacteria. The
intestinal villi were subsequently spread out on a glass
slide and a fluorescence microscope was used to visualize
the attached E. coli strains. Pictures were captured using an
MDS120 camera (Kodak, NY, USA). Strain B10, express-
ing the AF/R2 adhesin, was used as a positive control, and
strain DH5α as a negative control.
Animal experiments
For all experiments, four-week-old, newly weaned New
Zealand white rabbits (Versele-Laga) were used in accord-
ance with the Felasa guidelines []. On arrival (i.e. immedi-
ately after weaning), the rabbits were screened for the
presence of EPEC, Clostridium spiroforme and Eimeria spp.,
as described by Vandekerchove et al. [37]. The presence of
rotavirus was examined using a commercial ELISA kit
(Pathasure Enteritis ELISA kit, Vetoquinol Diagnostics,
France). Rabbits testing positive for Eimeria  spp. were
treated with Baycox (Bayer, Germany) according to the
manufacturer's instructions. The rabbits were housed
individually and received feed pellets and water ad libi-
tum. The daily feed intake, weight gain and diarrhea was
monitored at least three times a week. The diarrhea was
measured semi-quantitatively (0: no diarrhea, 1:
deformed feces, 2: sticky feces, 3: confluent feces, 4: liquid
feces). For all experiments, the shedding of E. coli was
semi-quantitatively monitored (0: no colonies; 4: conflu-
ent colonies) several times a week by taking rectal swabs
that were plated onto Simmons citrate agar (SCS) and/or
Gassner agar (G2S) [38]. Serum was collected once a week
from each rabbit. All rabbits, whether found dead or
euthanatized at the end of the experiment, were necrop-
sied.
Four animal experiments were performed: a first to deter-
mine the remaining virulence of the 97/241.6Δeae
mutant, and three vaccination-challenge experiments to
assess its immunoprotective features.
In vivo virulence of mutant 97/241.6Δeae
A total of 32 rabbits were allotted by weight and litter to
four homogenous groups of 8 rabbits each. Each rabbit in
all the groups received one ml of Penassay broth contain-
ing 0; 5 × 104; 5 × 106; and 5 × 108 colony forming units
(CFU) of the 97/241.6Δeae strain. The feed intake, weight
gain and occurrence of diarrhea were recorded for each
animal on a daily basis for a period of four weeks. The
groups were statistically compared using a repeated meas-
ures general linear model (SPSS Inc., Il., USA).
Vaccination experiment with a homologous challenge after seven 
days
In the first vaccination experiment, 42 rabbits were allot-
ted by weight and litter to three homogenous groups of 14
rabbits each. The first group was inoculated per os with
one ml of Penassay broth containing a dose of 2.5 × 105
CFU of mutant 97/241.6Δeae. One week later both this
group and the second group were infected with 5.4 × 104
CFU of wild-type REPEC 97/223.10. The third group was
used as an unvaccinated, unchallenged control group. The
experiment lasted for five weeks and the weight gain, feed
intake and occurrence of diarrhea were observed closely.
The groups were statistically compared using a mixed pro-
Table 1: Primers and cycle conditions used in this study
Primer Sequence Number of cycles (Cycle conditions)1
EAE FOR 5'AAAAAAGGATCCAAAAATTACGCCGGAAGAT 30 (15" 94°C; 30" 55.4°C; and 2' 68°C)
EAE REV 5'AAAAAATCTAGAAAAAGGTAAACAGGTCTC
248 FOR 5'CCACTCAAAAAACTGTCTGTTG 25 (15" 94°C; 30" 58.1°C; and 1' 72°C)
248 REV 5'TCCAGTGAACTACCGTCAAAG
ESPB FOR 5'GGATCCGAATACTATTGATTATACTAAT 30 (1' 94°C; 1' 52°C; and 2' 72°C)
ESPB REV 5' AAGCTTTAAACGTATCGACCATGAT
1 All PCRs, unless stated otherwise, were performed using 3U of recombinant Taq polymerase, 5 μl of PCR buffer including 2 mM MgCl2, 0.2 mM 
each of dNTP and 10 pmol of both forward and reverse primer.BMC Veterinary Research 2006, 2:22 http://www.biomedcentral.com/1746-6148/2/22
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cedure with the observed values of the animals before
infection used as a covariate (SAS Institute GmbH, Ger-
many). The unstructured covariance model was included
in the analysis to account for correlation between the
repeated measures. This covariance structure was chosen
by evaluating the Akaike's Information Criterion and was
preferable over the autoregressive (order 1) and the com-
pound symmetric structure. Although the autoregressive
(order 1) structure was preferable when evaluating the
variance-covariance structures with the Schwarz' Bayesian
Criterion, it did not have any influence on the significance
level of the parameters that were evaluated.
Vaccination experiment with a homologous challenge after four 
weeks
In the second vaccination-challenge experiment, 30 ani-
mals were allotted to three homogenous groups of 12, 12
and 6 animals on the basis of weight and litter. Upon
arrival, the first group was inoculated per os with one ml
of Penassay broth containing 108 CFU of mutant 97/
241.6Δeae. Four weeks later, this group and the second
group were challenged with 106 CFU of wild-type REPEC
97/223.10. The third group was used as a control group.
The experiments lasted for eight weeks in total and the
weight gain, feed intake and occurrence of diarrhea were
observed closely. The groups were statistically compared
using a repeated measures general linear model (SPSS).
Vaccination experiment with heterologous challenge after four weeks
The third vaccination-challenge experiment was con-
ducted using seven homogenous groups of 9 rabbits.
Upon arrival, 108 CFU of 97/241.6Δeae  (3-/O15) was
administered orally to groups 2, 4, and 6. Four weeks
later, all groups except the negative control group (group
1) were challenged with a virulent strain: groups 2 and 3
with 5 × 107 CFU of strain 82/90 (2+/O132), groups 4 and
5 with 2 × 107 CFU of strain 97/110.6 (8+/O103), and
groups 6 and 7 with 107 CFU of strain 00/195.1 (4+/O26).
The experiment lasted for eight weeks in total and the
weight gain, feed intake and occurrence of diarrhea were
observed closely. The groups were compared using a
mixed procedure with the observed values of the animals
before infection used as covariate as described above
(SAS).
Abbreviations
CFU colony forming units
FITC Fluoresceinisothiocyanate
G2S Gassner agar
IPTG isopropyl-beta-D-thiogalactopyranoside
LA Luria-Bertani agar
LB Luria-Bertani broth
LEE locus of enterocyte effacement
REPEC rabbit enteropathogenic Escherichia coli
SCS Simmons citrate agar
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